Opinion|Videos|November 22, 2023
Discussing Clinical Trial Enrollment for HER2-Positive Metastatic Breast Cancer With Your Oncologist
Author(s)Sara M. Tolaney, MD, MPH
Clinical trials should be considered at any point in a patient's journey with HER2-positive metastatic breast cancer, not just when standard options are exhausted, as they provide early access to promising therapies, novel combinations, and cutting-edge care.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Inside the ‘Weird and Wacky’ Frontier of New Targeted Therapy for Lung Cancer
2
FDA Approves Imdelltra for Extensive-Stage Small Cell Lung Cancer
3
FDA Approves Hyrnuo in Some with Locally Advanced/Metastatic NSCLC
4
FDA Grants Fast Track Status to New Gastric Cancer Treatment
5
